Pipeline

MMB102 is a GITR agonistic antibody designed to achieve an anti-cancer immune response via deactivation of immuno-suppressive Treg cells and activation of CD8+ effector T cells. MMB102 activates GITR by inducing crosslinking of GITR-GITRL complex, in contrast to the benchmark antibodies designed to mimic GITRL via direct binding with GITR.

• Differentiated epitope functional coverage compared to benchmark anti-GIT agonistic antibodies
• Preclinical evidence of anti-tumor activity in multiple cancer models
• Novel MoA: induction of strong cytotoxicity through GITR-crosslinking effect
• Enhanced proliferative capacity for long-term response